Most shareholders of Talecris Biotherapeutics will get a slightly sweeter deal under revised terms of the proposed $4 billion takeover by Grifols of Spain.
The companies altered the terms to settle a lawsuit by Talecris investors, according to a Securities and Exchange Commission filing. Talecris investors, including its more than 2,000 local workers, now will receive $19 in cash and 0.6485 of a Grifols share for each Talecris share they own.
Talecris board members and Cerberus Partners, the investment firm that owns 49 percent of Talecris, still will get the original terms, $19 in cash and 0.641 of a Grifols share.
The difference isn't much, less than 10 cents based on Grifols' closing price today. But it does mean that investors, who still need to vote on the deal, will have more incentive to approve it.